A5005635785- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Advanced biosensing and bioanalysis techniques
- Advanced Breast Cancer Therapies
- Chemical Reactions and Isotopes
- Lung Cancer Treatments and Mutations
Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention additional metastases after previous occurrence and local treatment in patients HER2+ cancer.Eligible had were within 12 weeks whole radiation therapy (WBRT), stereotactic radiosurgery, and/or surgery. Standard doses administered intravenously every 21 days (3.6 mg/kg) was given orally...
<p>Supplemental Fig 2. Total mutation Burden by MB.</p>
<p>Supplemental Methods</p>
<p>Supplemental Fig. 3. ERB-B-2 Status of Patients.</p>
<p>Supplemental Fig. 1. Neurocognitive assessments comparing patients presenting progression versus no progression.</p>
<p>Supplemental Fig. 4. Histogram illustrating ERBB2 relative copy number in plasma and CSF cfDNA samples from 12 patients during their T Tsamples T-DM1/TMZ combination therapy.</p>
<p>Supplemental Fig. 1. Neurocognitive assessments comparing patients presenting progression versus no progression.</p>
<p>Supplemental Fig 2. Total mutation Burden by MB.</p>
<p>Supplemental Methods</p>
<p>Supplemental Fig. 4. Histogram illustrating ERBB2 relative copy number in plasma and CSF cfDNA samples from 12 patients during their T Tsamples T-DM1/TMZ combination therapy.</p>
<p>Supplemental Fig. 3. ERB-B-2 Status of Patients.</p>
<div>AbstractPurpose:<p>Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention additional metastases after previous occurrence and local treatment in patients HER2<sup>+</sup> cancer.</p>Patients Methods:<p>Eligible had were within 12 weeks whole radiation therapy (WBRT), stereotactic radiosurgery, and/or...
<div>AbstractPurpose:<p>Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention additional metastases after previous occurrence and local treatment in patients HER2<sup>+</sup> cancer.</p>Patients Methods:<p>Eligible had were within 12 weeks whole radiation therapy (WBRT), stereotactic radiosurgery, and/or...
<div>AbstractPurpose:<p>Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention additional metastases after previous occurrence and local treatment in patients HER2<sup>+</sup> cancer.</p>Patients Methods:<p>Eligible had were within 12 weeks whole radiation therapy (WBRT), stereotactic radiosurgery, and/or...
<p>Supplemental Methods</p>
<p>Supplemental Fig. 4. Histogram illustrating ERBB2 relative copy number in plasma and CSF cfDNA samples from 12 patients during their T Tsamples T-DM1/TMZ combination therapy.</p>
<p>Supplemental Fig. 1. Neurocognitive assessments comparing patients presenting progression versus no progression.</p>
<p>Supplemental Fig 2. Total mutation Burden by MB.</p>
<p>Supplemental Fig. 3. ERB-B-2 Status of Patients.</p>
<p>Supplemental Methods</p>
<p>Supplemental Fig. 4. Histogram illustrating ERBB2 relative copy number in plasma and CSF cfDNA samples from 12 patients during their T Tsamples T-DM1/TMZ combination therapy.</p>
<p>Supplemental Fig 2. Total mutation Burden by MB.</p>
<p>Supplemental Fig. 1. Neurocognitive assessments comparing patients presenting progression versus no progression.</p>
<p>Supplemental Fig. 3. ERB-B-2 Status of Patients.</p>